Wegovy vs. Zepbound

Wegovy vs Zepbound: the direct finding

Wegovy contains semaglutide. Zepbound contains tirzepatide. SURMOUNT-5 is the key head-to-head obesity study because it compared those active medicines in adults with obesity without diabetes over 72 weeks.

Tirzepatide produced 20.2% average weight loss versus 13.7% with semaglutide. At least 20% weight loss occurred in 64.6% of the tirzepatide group and 40.1% of the semaglutide group. Discontinuation for adverse events was 6.1% and 8.0%, respectively.

SURMOUNT-5 was not a loose comparison of two brand pages. It randomized 751 adults with obesity without diabetes to maximum tolerated tirzepatide or semaglutide and followed them for 72 weeks. That population is why the study is the strongest source for the central weight-management question, while it does not answer diabetes treatment questions.

Which product tends to fit which decision

For the specific outcome measured in SURMOUNT-5, Zepbound tended to win on average weight loss and the proportion reaching 20% loss. Wegovy remains a labeled chronic-weight-management option and may fit when its label, prior response, access, tolerability, or coverage path is more favorable.

Use the decision table below as a discussion guide: start with the chronic-weight-management label, then weigh the direct trial result, product-specific warnings, insurance or cash access, and the total program structure. Do not treat a headline price as a clinical ranking.

The headline result is clear. Mean body-weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The share reaching at least 20% weight loss was 64.6% and 40.1%, respectively. Both are meaningful group outcomes, and the larger tirzepatide result is a reason Zepbound should be presented as the stronger average-weight-loss option in this exact trial.

What SURMOUNT-5 found

SURMOUNT-5 randomized adults with obesity, without type 2 diabetes, to maximum tolerated tirzepatide or maximum tolerated semaglutide and followed them for 72 weeks. The publication reported greater mean weight reduction and waist-circumference reduction with tirzepatide in the study population.

That finding is not a universal scorecard. It does not erase contraindications, access barriers, preferences, treatment response, or the fact that people do not experience an average result.

The study also gives a useful tolerability datapoint rather than a vague safety disclaimer: adverse-event discontinuation was 6.1% with tirzepatide and 8.0% with semaglutide. Gastrointestinal events were common. Readers considering either product still need the product-specific label review, particularly when symptoms are severe, persistent, or accompanied by dehydration, significant abdominal pain, allergic symptoms, or other concerning changes.

Safety and tolerability are part of the comparison

Both labels require attention to contraindications, warnings, and interactions. Gastrointestinal events were common in the direct trial and occurred mainly during dose escalation, but a page should not reduce safety to a generic nausea paragraph.

Readers should contact the treating team for severe or persistent abdominal pain, significant vomiting or diarrhea, allergic-reaction symptoms, or concerning new symptoms. Seek urgent care for chest pain, trouble breathing, fainting, confusion, or a severe allergic reaction.

Wegovy is not made irrelevant by the trial result. It remains a chronic-weight-management product with its own label, access landscape, and treatment history. A good comparison names the average winner first, then makes clear that an existing response, coverage, availability, adverse-effect experience, and care model can materially change the workable option.

This article does not provide a titration, conversion, or switching plan. Product labels and clinical guidance are product-specific.

Cost needs a clean denominator

One program may quote care only while a pharmacy bills medication separately. Another may include medication if prescribed, follow-up, supplies, and shipping. A lower number is not automatically a lower recurring total.

The price comparison below separates unlike structures. It should show whether a figure is ongoing, introductory, prepaid, medication-inclusive, or incomplete, plus the date the provider fact was checked.

Compare commercial offers only after the clinical comparison is understandable. The relevant denominator is an ongoing, like-for-like total: medication inclusion if prescribed, clinical follow-up, refill interval, shipping, and membership or prepayment. The catalog can show those live terms; it should never turn its price ranking into an effectiveness ranking.

• Compare the same refill interval.
• Separate drug cost from clinician or membership cost.
• Treat insurance and savings claims as conditional until verified.
• Do not use a manufacturer price to infer a telehealth checkout total.

What shared decision-making looks like

Current obesity guidance emphasizes benefits, harms, costs, access, comorbidities, and individual preferences. That framing is more useful than a universal ranking because it leaves room for clinical context and practical access constraints.

A transparent telehealth page can help readers prepare questions. It should not promise a prescription or call an advertised plan suitable for everyone.

A page that stays current

This draft should be refreshed whenever either label changes, a direct comparison is corrected or superseded, or the program catalog changes. The date beside a price is as important as the number itself.

If current evidence cannot answer a question, say so. That restraint protects readers from a confident but unsupported comparison.